Past Successes

Meningococcal Group B Vaccine for adolescents 16-18 years of age
If interested please call our Hohensee Location and ask to speak to Tawsha 402-327-6067 or our Salt Creek Circle Location and ask to speak to Rosie 402-327-6067, or our Northwoods Location and ask to speak to Delilah 402-327-6064

Meningococcal Group B Vaccine for Healthy Infants
If interested please call our Hohensee Location and ask to speak to Tawsha 402-327-6067

Infant Formula Study for <2 weeks of age, containing a new prebiotic and probiotic mix. If interested please call our Northwoods Location and ask to speak to Amy 402-327-6064

Safety and efficacy of Tapinarof for the treatment of Atopic Dermatitis in >2 year old children. If interested please call our Hohensee Location and ask to speak to Tawsha 402-327-6067

Meningococcal Vaccine for infants 6 to 7 months of age. If interested please call our Salt Creek Circle Location and ask to speak to Rosie 402-327-6068, or our Northwoods Location and ask to speak to Amy 402-327-6064

RSV Vaccine for healthy pre-term and full-term infants. If interested please call our Salt Creek Circle location and ask to speak to Rosie 402-327-6068.

Pfizer B7471014               

Started: 11/2020

Study Name: A phase 3, single-arm trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy children 15 months through 17 years of age

Indication: Pneumococcal

Principal Investigators: Luke Anschutz, Dave Meduna

Started: 11/2020

Study Name: A randomized, double-blind, placebo-controlled, multicenter, 16-week trial to evaluate the efficacy and safety of xxx in children, adolescent and adult subjects (ages 2 years and older) with mild to moderate atopic dermatitis

Indication: Atopic Dermatitis

Principal Investigator: Sahra Niazi

Started: 3/2020

Study name: A phase 3, randomized, double- or observer-blinded, placebo-controlled trial to evaluate the efficacy and safety of a respiratory syncytial virus (rsv) perfusion subunit vaccine in infants born to women vaccinated during pregnancy

Indication: RSV/OB

Principal Investigator: Brad Brabec

Started: 2/2020

Study name: A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infants

Indication: Pneumococcal

Principal Investigators: Brad Brabec, Dave Meduna

Started: 9/2019

Study Name: Immunogenicity and Safety of a Booster Dose of an Investigational xxx Meningococcal Conjugate Vaccine in Adolescents and Adults

Indication: Meningitis

Principal Investigators: Paul Bernhardson, Brad Brabec, Steve Russell

Started: 9/2019

Study Name: A phase 3 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of xxx, a monoclonal antibody with an extended half-life against respiratory syncytial virus, in healthy late preterm and term infants (melody)

Indication: RSV

Principal Investigator: Steve Russell

Started: 9/2019

Study name: A longitudinal study to evaluate various skin health biophysical measures preceding diaper dermatitis in newborns

Indication: None Specified Skin Study

Principal Investigator:  Amy Bargen

Started: 9/2019

Study Name: An exploratory study to identify the composition of the microbiome of healthy diapered skin in eight to twelve month old infants.

Indication: None Specified Skin Study

Principal Investigator: Amy Bargen

Started: 9/2019

Study Name A phase 2b, randomized, placebo-controlled, observer-blinded trial to evaluate the safety, tolerability, and immunogenicity of a respiratory syncytial virus (rsv) vaccine in pregnant women 18 through 49years of age and their infants

Indication: RSV/OB

Principal Investigator: Brad Brabec

Started: 6/2019

Study Name: A phase III, observer-blind, randomized, multi-country study to assess the  reactogenicity and safety of the Porcine circovirus (PCV) free liquid formulation of GSK’s oral live attenuated human rotavirus (HRV) vaccine as compared to the xxx the GSK’s HRV vaccine, when administered as a 2-dose vaccination in infants starting at age 6-12 weeks.

Indication: RSV

Principal Investigators: Sahra Niazi, Steve Russell, Pam Zegers

Started: 9/2018

Study Name: A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants (PNEU-PED)

Indication: Pneumococcal

Principal Investigator: Luke Anschutz, Paul Bernhardson

Started: 4/2019

Study Name: Tolerance, Compliance and Growth of Infants Fed an Extensively Hydrolyzed Infant Formula with Added Human Milk Oligosaccharides

Indication: Nutrition

Principal Investigator: Pam Zegers

Started: 11/2018

Study Name: Evaluation of growth, safety, and efficacy of a term infant formula for healthy infants

Indication: Nutrition

Principal Investigator: Paul Bernhardson

Started: 3/2018

Study Name: An Exploratory study to determine if there are microbiome and skin surface protein profiles associated with diaper rash in infants (9-12 months)

Indication: Skin Assessment

Principal Investigator: Sahra Niazi

Started: 8/2018

Study Name: A Phase III Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddler

Indication: Meningitis

Principal Investigator: Amy Bargen, Steve Russell

Started: 10/2018

Study Name: Protocol Title: A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of XXX and Prevnar 13™ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)

Indication: Pneumococcal

Principal Investigators: Luke Anschutz, Paul Bernhardson, Brad Brabec, Steve Russell

Started: 7/2018

Study Name: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of XXX Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 years and older) with Molluscum Contagiosum

Indication: Molluscum

Principal Investigator: Brad Brabec